HIGHLIGHTS The US FDA has granted Fast Track Designation to Amplia's lead drug narmafotinib in advanced pancreatic cancer Fast Track Designation facilitates the development of investigational drugs and allows for expedited review MELBOURNE, Australia, Sept. 19, 2024 /PRNewswire/ -- Amplia...
FDA FAST TRACK DESIGNATION FOR NARMAFOTINIB IN ADVANCED PANCREATIC CANCER
Seaking AlphaSeeking Alpha / Seaking Alpha 3 hours ago 1 Views
Comments